Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04646941
Other study ID # 2020-025
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 10, 2020
Est. completion date January 31, 2024

Study information

Verified date August 2023
Source The First Affiliated Hospital of Xiamen University
Contact Changqin Liu, Dr.
Phone +86-592-2137796
Email liuchangqin@xmu.edu.cn
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To follow up the progress of chronic complications in T2DM patients who had undergone anthropometric measurements, laboratory testing and standard overnight polysomnography monitor from 2013 to 2018.


Description:

Obstructive sleep apnea (OSA) is a common chronic sleep disorder and a frequent comorbidity in patients with type 2 diabetes. There has been increasing recognition that OSA is highly prevalent in persons with type 2 diabetes. This study is to explore the relationship between OSA and the progress of chronic diabetes-related complications in type 2 diabetes who had undergone anthropometric measurements, laboratory testing and standard overnight polysomnography monitor from 2013 to 2018 in the Department of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, Xiamen, China.


Recruitment information / eligibility

Status Recruiting
Enrollment 330
Est. completion date January 31, 2024
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Type 2 diabetes - Age:18-80 Exclusion Criteria: - Patients with non type 2 diabetes mellitus - Preparation for pregnancy - Lactation patients - Patients with uncontrolled thyroid disease - Patients with severe cardiovascular disease - Patients with severe hepatic and renal insufficiency - Patients with oral and maxillofacial malformations and upper respiratory tract malformations - Patients with pulmonary infection or COPD - Patients who are not willing to accept the questionnaire survey - Unable to sign informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Other:
regular treatment
The patients with or without OSA received regular hypoglycemic drugs.

Locations

Country Name City State
China The first affiliated hospital of Xiamen university Xiamen Fujian

Sponsors (1)

Lead Sponsor Collaborator
The First Affiliated Hospital of Xiamen University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary the progress of diabetic complications Diabetic complications include diabetic microvascular complications, atherosclerotic cardiovascular disease(ASCVD), and Diabetic foot disease.
Diabetic microvascular complications include diabetic nephropathy, diabetic retinopathy and diabetic neuropathy.
Diabetic macrovascular complications refer to ASCVD, which is defined as coronary heart disease (CHD; acute and silent MI, and unstable angina), ischemic stroke, or peripheral artery disease (PAD).
From January 1, 2013 to December 31, 2020
Primary the new onset and types of tumor in T2DM patients the new onset and types of tumor in T2DM patients From January 1, 2013 to December 31, 2020